Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay

Cancer Chemotherapy and Pharmacology

Volumn 38, Issue 3, 1996, Pages 225-232

  Aherne, G Wynne ^a   Hardcastle, Anthea ^a   Valenti, Melanie ^a   Bryant, Alexander ^a   Rogers, Paul ^a   Pettit, George R ^b   Srirangam, Jayaram K ^b   Kelland, Lloyd R ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Cytotoxicity; Dolastatins; P glycoprotein; Radioimmunoassay; Xenograft

Indexed keywords

CISPLATIN; DOLASTATIN 10; DOLASTATIN 15; DOXORUBICIN; GLYCOPROTEIN P; PACLITAXEL; PEPTIDE; UNCLASSIFIED DRUG; VERAPAMIL; VINBLASTINE;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CELL CULTURE; CANCER GRAFT; CANCER INHIBITION; CELL GROWTH; COLON CARCINOMA; CONTROLLED STUDY; CROSS RESISTANCE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RESISTANCE; FEMALE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; OVARY CARCINOMA; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA; CELL DIVISION; COLONIC NEOPLASMS; CROSS REACTIONS; DEPSIPEPTIDES; DRUG RESISTANCE, MULTIPLE; FEMALE; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; OLIGOPEPTIDES; OVARIAN NEOPLASMS; RABBITS; RADIOIMMUNOASSAY; RANDOM ALLOCATION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; VERAPAMIL;

EID: 0029953141     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050475     Document Type: Article

References (30)

1. Bai R, Pettit GR, Hamel E (1990) Dolastatin 10, a powerful cytostatic peptide derived from a marine animal: inhibition of tubulin polymerisation mediated through the vinca alkaloid binding domain. Biochem Pharmacol 39: 1941
2. Bai R, Friedman SJ, Pettit GR, Hamel E (1992) Dolastatin 15, a potent antimitotic depsipeptide derived from Dolabella auricularia. Biochem Pharmacol 43: 2637
3. Beckwith M, Urba WJ, Longo DL (1993) Growth inhibition of human lymphoma cell lines by the marine products, dolastatins 10 and 15. J Natl Cancer Inst 85: 483
4. Hamel E (1992) Natural products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B. Pharmacol Ther 55: 31
5. Harrap KR, Jones M, Siracky J, Pollard L, Kelland LR (1990) The establishment, characterization and calibration of human ovarian carcinoma xenografts for the evaluation of novel platinum anticancer drugs. Ann Oncol 1: 65
6. Hills CA, Kelland LR, Abel G, Siracky J, Wilson AP, Harrap KR (1989) Biological properties often human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. Br J Cancer 59: 527
7. Kelland LR, Abel G (1992) Comparative in vitro cytotoxicity of taxol and taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 30: 444
8. Kelland LR, Mistry P, Abel G, Loh SY, O'Neill CF, Murrer BA, Harrap KR (1992) Mechanism-related circumvention of acquired cis-diamminedichloroplatinum (II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum (IV) dicarboxylates. Cancer Res 52: 3857
9. Kelland LR, Abel G, McKeage MJ, Jones M, Goddard PM, Valenti M, Murrer BA, Harrap KR (1993) Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum (IV): an orally active platinum drug. Cancer Res 53: 2581
10. Kepler JA, Taylor GF (1993) Preparation of tritium labelled dolastatin-10. Proc Am Assoc Cancer Res 34: 371
11. Leu J-G, Jech KS, Wheeler NC, Chen B-X, Erlanger BF (1993) Immunoassay of taxol and taxol-like compounds in plant extracts. Life Sci 53: 183
12. Ling V (1992) P-glycoprotein and resistance to anticancer drugs. Cancer 69: 2603
13. Mistry P, Kelland LR, Abel G, Sidhar S, Harrap KR (1991) The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br J Cancer 64: 215
14. Newman RA, Fuentes A, Covey JM, Benvenuto JA (1994) Pre-clinical pharmacology of the natural marine product dolastatin 10 (NSC 376128). Drug Metab Dispos 22: 428
15. Patino N, Frerot E, Galeotti N, Poncet J, Coste J, Dufour MN, Jouin P (1992) Total synthesis of the proposed structure of dolastatin 15. Tetrahedron 48: 4115
16. Pettit GR, Kamano Y, Herald CL, Tuinman AA, Boettner FE, Kizu H, Schmidt JM, Baczynskyj L, Tomer KB, Bontems RJ (1987) The isolation and structure of a remarkable marine animal antineoplastic constituent: dolastatin 10. J Am Chem Soc 109: 6883
17. Pettit GR, Kamano Y, Kizu H, Dufresne C, Herald CL, Bontems RJ, Schmidt JM, Boettner FE, Nieman RA (1989a) Isolation and structure of the cytostatic linear depsipeptide dolastatin 15. J Org Chem 54: 6005
18. Pettit GR, Singh SB, Hogan F, Lloyd-Williams P, Herald DL, Burkett DD, Clewlow PJ (1989b) The absolute configuration and synthesis of natural (-)-dolastatin 10. J Am Chem Soc 111: 5463
19. Pettit GR, Herald DL, Singh SB, Thornton TJ, Mullany JT (1991) Antineoplastic agents. 220. Synthesis of natural (-)-dolastatin 15. J Am Chem Soc 113: 6692
20. Pettit GR, Kamano Y, Herald CL, Fujii Y, Kizu H, Boyd MR, Boettner FE, Doubek DL, Schmidt JM, Chapuis JC, Michel C (1993) Isolation of dolastatins 10-15 from the marine mollusc Dolabella auricularia. Tetrahedron 49: 9151
21. Pettit GR, Kantoci D, Herald DL, Barkoczy J, Slack JA (1994) Procedures for the analyses of dolastatins 10 and 15 by high performance liquid chromatography. J Liquid Chromatogr 17: 191
22. Raynaud F, Kelland LR, Walton MI, Judson IR (1994) Preclinical pharmacology of 1069C85, a novel tubulin binder. Cancer Chemother Pharmacol 35: 169
23. Reid JM, Walker DL, Ames MM (1995) Evaluation of an L1210 bioassay and HPLC for determination of dolastatin 10 in human and murine plasma. Proc Am Assoc Cancer Res 36: 364
24. Roux F, Maugras I, Poncet J, Niel G, Jouin P (1994) Synthesis of dolastatin 10 and (R-Doe)-dolastatin 10. Tetrahedron 50: 5345
25. Sharp SY, Rowlands MG, Jarman M, Kelland LR (1994) Effects of a new antioestrogen, idoxifene, on cisplatin- and doxorubicin-sensitive and -resistant human ovarian carcinoma cell lines. Br J Cancer 70: 409
26. Steube KG, Grunicke D, Pietsch T, Gignac SM, Pettit GR, Drexler HG (1992) Dolastatin 10 and dolastatin 15: effects of two natural peptides on growth and differentiation of leukemia cells. Leukemia 6: 1048
27. Teale JD, Clough JM, Marks V (1977) Radioimmunoassay of vinblastine and vincristine. Br J Cancer 4: 169
28. Toppmeyer DL, Slapak CA, Croop J, Kufe DW (1994) Role of P-glycoprotein in dolastatin 10 resistance. Biochem Pharmacol 48: 609
29. Valenti MR, Sharp SY, Kelland LR (1995) Characterization of an acquired etoposide resistant human ovarian cell line possessing an atypical pattern of cross-resistance. Br J Cancer 71: 43
30. Waud WR, Dykes DJ, Pettit GR, Plowman J (1993) Preclinical antitumor activity of dolastatin 10. Proc Am Assoc Cancer Res 34: 383